Literature DB >> 15831148

The cardiac ryanodine receptor (RyR2) and its role in heart disease.

Ying Taur1, William H Frishman.   

Abstract

The cardiac ryanodine receptor has become a subject of increasing interest as its role in the etiology of cardiac disease is becoming more apparent. In this article, we review the current knowledge of the structure and function of the cardiac ryanodine receptor and its implications in cardiac pathophysiology. Cardiac ryanodine receptors function by regulating calcium release from the sarcoplasmic reticulum in cardiomyocytes, thereby playing an integral role in excitation-contraction coupling. In heart failure, the myocardium remains in a chronic hyperadrenergic state. This leads to protein kinase A hyperphosphorylation of ryanodine receptors within cardiomyocytes, ultimately leading to calcium leakage from the sarcoplasmic reticulum into the cytosol and thus impairing excitation-contraction coupling. These mechanisms could partially explain the pathophysiology underlying the reduced cardiac output seen in heart failure. Beta-adrenergic blockade appears to correct the abnormality and reestablishes normal ryanodine receptor function. These calcium leaks can also generate delayed afterdepolarizations, which can lead to fatal arrhythmias. Two genetic diseases have been linked to mutations in the cardiac ryanodine receptor: arrhythmogenic right ventricular dysplasia type 2 and catecholaminergic polymorphic ventricular tachycardia or familial polymorphic ventricular tachycardia. As our understanding of this receptor and its modulators deepens, the possibility of clinical application draws near.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15831148     DOI: 10.1097/01.crd.0000128709.84812.86

Source DB:  PubMed          Journal:  Cardiol Rev        ISSN: 1061-5377            Impact factor:   2.644


  7 in total

1.  Hyperphosphorylation of the cardiac ryanodine receptor at serine 2808 is not involved in cardiac dysfunction after myocardial infarction.

Authors:  Hongyu Zhang; Catherine A Makarewich; Hajime Kubo; Wei Wang; Jason M Duran; Ying Li; Remus M Berretta; Walter J Koch; Xiongwen Chen; Erhe Gao; Héctor H Valdivia; Steven R Houser
Journal:  Circ Res       Date:  2012-02-02       Impact factor: 17.367

2.  Mice with the R176Q cardiac ryanodine receptor mutation exhibit catecholamine-induced ventricular tachycardia and cardiomyopathy.

Authors:  Prince J Kannankeril; Brett M Mitchell; Sanjeewa A Goonasekera; Mihail G Chelu; Wei Zhang; Subeena Sood; Debra L Kearney; Cristina I Danila; Mariella De Biasi; Xander H T Wehrens; Robia G Pautler; Dan M Roden; George E Taffet; Robert T Dirksen; Mark E Anderson; Susan L Hamilton
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-27       Impact factor: 11.205

3.  Effect of changes in action potential spike configuration, junctional sarcoplasmic reticulum micro-architecture and altered t-tubule structure in human heart failure.

Authors:  M B Cannell; D J Crossman; C Soeller
Journal:  J Muscle Res Cell Motil       Date:  2006-08-04       Impact factor: 2.698

4.  Identification of novel genes significantly affecting growth in catfish through GWAS analysis.

Authors:  Ning Li; Tao Zhou; Xin Geng; Yulin Jin; Xiaozhu Wang; Shikai Liu; Xiaoyan Xu; Dongya Gao; Qi Li; Zhanjiang Liu
Journal:  Mol Genet Genomics       Date:  2017-12-12       Impact factor: 3.291

Review 5.  NOX2 As a Target for Drug Development: Indications, Possible Complications, and Progress.

Authors:  Becky A Diebold; Susan M E Smith; Yang Li; J David Lambeth
Journal:  Antioxid Redox Signal       Date:  2014-03-24       Impact factor: 8.401

6.  Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?

Authors:  U Deniz Dincer
Journal:  Diabetes Metab Syndr Obes       Date:  2012-04-05       Impact factor: 3.168

7.  ETV1 activates a rapid conduction transcriptional program in rodent and human cardiomyocytes.

Authors:  Akshay Shekhar; Xianming Lin; Bin Lin; Fang-Yu Liu; Jie Zhang; Alireza Khodadadi-Jamayran; Aristotelis Tsirigos; Lei Bu; Glenn I Fishman; David S Park
Journal:  Sci Rep       Date:  2018-07-02       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.